Virpax Pharmaceuticals, Inc.
VRPX
$0.6695
-$0.5505-45.12%
| Weiss Ratings | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.00 | |||
| Price History | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -56.81% | |||
| 30-Day Total Return | -89.80% | |||
| 60-Day Total Return | -93.25% | |||
| 90-Day Total Return | -95.46% | |||
| Year to Date Total Return | -92.85% | |||
| 1-Year Total Return | -99.35% | |||
| 2-Year Total Return | -99.66% | |||
| 3-Year Total Return | -99.88% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -99.36% | |||
| 52-Week Low % Change | 48.78% | |||
| Price | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $104.28 | |||
| 52-Week Low Price | $0.45 | |||
| 52-Week Low Price (Date) | Apr 03, 2025 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 711.35K | |||
| Enterprise Value | -801.71K | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -137.61 | |||
| Earnings Per Share Growth | -59.19% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.42 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.67 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | 0.07 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 9.60M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 610 727 4597 | |||
| Address | 1055 Westlakes Drive Berwyn, PA 19312 | |||
| Website | www.virpaxpharma.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -135.02% | |||
| Return on Equity | -- | |||
| Income Statement | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -12.08M | |||
| Net Income (TTM) | -12.07M | |||
| Net Income Avl. to Common (TTM) | -12.07M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 25.68% | |||
| EPS Diluted (TTM) | -137.61 | |||
| EPS Diluted Growth (Q YOY) | 90.57% | |||
| Balance Sheet | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.51M | |||
| Cash Per Share (Q) | $0.16 | |||
| Total Current Assets (Q) | 1.56M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -913.80K | |||
| Current Ratio (Q) | 0.630 | |||
| Book Value Per Share (Q) | -$1.60 | |||
| Total Assets (Q) | 1.56M | |||
| Total Current Liabilities (Q) | 2.47M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 2.47M | |||
| Total Common Equity (Q) | -913.80K | |||
| Cash Flow | VRPX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 9.08M | |||
| Net Change in Cash (TTM) | -7.63M | |||
| Levered Free Cash Flow (TTM) | -12.26M | |||
| Cash from Operations (TTM) | -16.71M | |||
